Medtronic Secures Permanent CPT Codes for Urinary Incontinence and Hypertension Devices
Event summary
- Medtronic received Category I CPT code approvals for Altaviva™ (urinary incontinence) and Symplicity Spyral™ (hypertension) systems, replacing existing Category III codes.
- New codes take effect January 2028, signaling established clinical adoption and reimbursement pathway progress.
- Altaviva™ gained FDA approval in September 2025; Symplicity Spyral™ secured Medicare coverage in October 2025.
- Altaviva™ targets 16M U.S. adults with urge urinary incontinence; Symplicity Spyral™ leverages global clinical data from 5,000+ patients.
The big picture
Medtronic's CPT wins validate its strategy to address high-prevalence conditions with minimally invasive solutions. The approvals come as renal denervation regains traction post-clinical trial validation and urinary incontinence devices expand beyond traditional stimulation therapies. With Medicare coverage already secured for Symplicity Spyral™, the remaining hurdle is commercial payer alignment—a dynamic Medtronic now aims to accelerate through Category I code leverage.
What we're watching
- Reimbursement Momentum
- Whether Category I codes accelerate commercial payer coverage decisions for both systems.
- Clinical Adoption
- The pace at which physician utilization scales post-code implementation in January 2028.
- Competitive Positioning
- How Medtronic defends market share against emerging renal denervation and neuromodulation alternatives.
